Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Enrolling by invitation × olaparib × Clear all

Phase

Status

Active not recruiting 47 Completed 39 Recruiting 36 Unknown 20 Terminated 14 Withdrawn 9 Not yet recruiting 6 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 1

Interventions

130-nm albumin-bound paclitaxel 3 camrelizumab 2 S 1 (combination) 2 Fluorodeoxyglucose F18 2 Cisplatin 2 Bevacizumab 2 trilaciclib 1 trastuzumab deruxtecan 1 sintilimab 1 selinexor 1 sacituzumab govitecan 1 ribociclib 1 olaparib 1 nimotuzumab 1 lenvatinib 1 durvalumab 1 decitabine and cedazuridine drug combination 1 dalpiciclib 1 cemiplimab 1 anlotinib 1 abemaciclib 1 Valacyclovir 1 Temozolomide 1 Taxes 1 Surgical Procedures, Operative 1 Specimen Handling 1 Radiotherapy 1 Radiosurgery 1 Platinum 1 Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06419179 2025-05-20

GUIDANCE

University of Cologne

Phase 2 Enrolling by invitation

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡